(Q48234725)

9 February 2018

title

Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. (English)

1 reference

9 February 2018

1 reference

7

Keith T Flaherty

1 reference

9 February 2018

3

Andrzej Niemierko

1 reference

9 February 2018

author name string

Daniel A Wattson

1

1 reference

9 February 2018

Ryan J Sullivan

2

1 reference

9 February 2018

Ryan M Merritt

4

1 reference

9 February 2018

Donald P Lawrence

5

1 reference

9 February 2018

Kevin S Oh

6

1 reference

9 February 2018

Helen A Shih

8

1 reference

9 February 2018

publication date

12 April 2015

1 reference

9 February 2018

Journal of Neuro-Oncology

published in

1 reference

9 February 2018

volume

123

1 reference

9 February 2018

issue

1

1 reference

9 February 2018

page(s)

75-84

1 reference

9 February 2018

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Determinants of survival in patients with brain metastases from cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Pathologic and gene expression features of metastatic melanomas to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1761-X

Prognostic factors for survival in melanoma patients with brain metastases

21 January 2018

1 reference

12 December 2020

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

Vemurafenib and radiation therapy in melanoma brain metastases

1 reference

12 December 2020

10.1007/S11060-015-1761-X

Identifiers

DOI

1 reference

9 February 2018

1 reference

9 February 2018